Identification of the need and uses of a reference standard

Similar documents
European Pharmacopoeia Reference Standards A Lodi, Head of the Laboratory Department, EDQM, Council of Europe

11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS. Siriphorn Laomanacharoen 21 December 2012

Pharmacopoeial Reference Standards

Impurity Control in the European Pharmacopoeia

STANDARD OPERATING PROCEDURES. Handling and working with Analytical Standards

SPECIFIC MONOGRAPHS. A Guide Through The Different Sections. Claude Coune

VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY *)

General concepts in the Ph. Eur.: theory and rationale

Guide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia

CONCEPT PAPER FOR COMMENT

Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance

Primary / secondary standards in pharmaceutical QC. Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

VICH Topic GL2 (Validation: Methodology) GUIDELINE ON VALIDATION OF ANALYTICAL PROCEDURES: METHODOLOGY

How to prepare an application for revision of a CEP

9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization

PHARMACEUTICAL REFERENCE STANDARDS

DIDANOSINE ORAL POWDER Final text for addition to The International Pharmacopoeia

Certificate of Analysis

General European OMCL Network (GEON) QUALITY MANAGEMENT DOCUMENT

Analytical Method Transfer Program. Richard B. Nguyen. Associate Scientific Liaison, Chemical Medicines, USP

Certificate of Analysis

Validation of Analytical Methods used for the Characterization, Physicochemical and Functional Analysis and of Biopharmaceuticals.

Proposals for the Guideline on Classification of Variations. Only those variations applicable to the active substance are listed.

Certificate of Analysis

How the European Pharmacopoeia Provides the Framework to Implement QbD Principles

European Regulations for Medicines. Place and Role of the European Pharmacopoeia in Europe Ph. Eur. concept

Certificate of Analysis

Additional guidance on: TNsG on Data Requirements, Part A, Chapter 2, Point 4. Analytical Methods for Detection and Identification.

Certificate of Analysis

Characterisation of non-compendial reference standards for impurities: How good is good enough?

Inspection of Quality Control Laboratories

Certificate of Analysis

The European Pharmacopoeia

Certificate of Analysis

Final Report. Characterisation of Sample Report. Job No 2016/11/12-34 AS No. 1234A. Client Example Contact Sample. Signed. Example report.

NIRS, PAT, RTR testing EU experience and regulatory perspective

Ph. Eur. monographs and biosimilars

Certificate of Analysis

Certificate of Analysis

Certified Reference Material - Certificate of Analysis

Wirkstoffdokumentation & CEP- Verfahren

Implementation of the ICH Q3D guideline in the Ph. Eur.

HEPARIN CALCIUM. Heparinum calcicum

Comments concerning revised texts published in Supplement 9.5

Certificate of Analysis

Certificate of Analysis

A Simple Rapid and Sensitive Method Development for Quantification of Quetiapine Fumarate in Bulk and Dosage Forms Using RP-HPLC

GOOD CHROMOTOGRAPHY PRACTICES (February 2019) DRAFT FOR COMMENTS

How to build a good CEP application - ICH Q3D

Impurities from degradation of Drug Substances

EDQM Overview of our products and services

Certificate of Analysis

Certificate of Analysis

Certified Reference Material - Certificate of Analysis

OMCL Network of the Council of Europe QUALITY ASSURANCE DOCUMENT

Certificate of Analysis

Guidelines for Pharmaceutical Equivalence Requirements

Optimizing the Purification of a Standard Chiral Compound Utilizing a Benchtop, Multi-Purpose, Semi-Preparative to Preparative HPLC System

Certificate of Analysis

EDQM Conference. The European Pharmacopoeia Is it prepared for the future? Workshop 5. Workshop October 2010 Prague, Czech Republic

Cleaning validation of cleanrooms and preparation equipments

Annex 1. Good pharmacopoeial practices

Reference Standard? Mitzi Rettinger, Uma Sreenivasan, PhD, Isil Dilek, PhD, Sherri Pogue C illi t C ti

Certificate of Analysis

European Directorate for the Quality of Medicines & HealthCare (EDQM)

Guideline on setting specifications for related impurities in antibiotics

Overview of USP Activities and How to Get Involved

Certified Reference Material - Certificate of Analysis

CRITICAL ASPECT ANALYTICAL TEST REVIEW

Writing a Convincing Dossier on Impurities and Method Validation. Dr. Hans Ulrich Gally Swissmedic Swiss Agency for Therapeutic Products

The European Pharmacopoeia and the 3Rs

ICH Q2(R1) A Primer. cgmp. GxP PIC/S SOP ISO QA/QC LOD/LOQ. Validation of Analytical Methods API EP FDA OECD GCP

Certified Reference Material - Certificate of Analysis

Certified Reference Material - Certificate of Analysis

Certified Reference Material - Certificate of Analysis

Technical guide for the ELABORATION AND USE OF MONOGRAPHS ON HUMAN PLASMA- DERIVED PRODUCTS

DACLATASVIR TABLETS (DACLATASVIRI COMPRESSI) Proposal for The International Pharmacopoeia. (May 2018)

CHAPTERS 1, 2 and 3 CHAPTER-4 CHAPTER-5,

Certification of suitability to the Monographs of the European Pharmacopoeia

High Quality, Certified Snap-N-Shoot Sh Standards d of Reb A and Stevia Impurities ensure accuracy and Cerilliant Corporation

Comments concerning revised texts published in Supplement 9.4

INTERNATIONAL PHARMACOPOEIA MONOGRAPH ON ARTEMETHER AND LUMEFANTRINE CAPSULES REVISED DRAFT FOR DISCUSSION

Certified Reference Material - Certificate of Analysis

Perspectives on Method Validation: Importance of Adequate Method Validation

á1225ñ VALIDATION OF COMPENDIAL PROCEDURES

Chemical Aspects of Stability Evaluation

Revision of 30 April 2013 draft, 4 November 2013

European Medicines Agency Evaluation of Medicines for Human Use

Analytical Methods Development and Validation

Salient Features of IP-2010 (VI edition)

Australian Government

Overview of comments received on 'Draft Guideline on the chemistry of active substances (veterinary) (EMA/CVMP/QWP/49477/2017)

Reference Standards for Monoclonal Antibodies: Key Challenges Addressed

EDQM Overview of our products and services

Analytical Procedures and Methods Validation for Drugs and Biologics

International Journal of Institutional Pharmacy and Life Sciences 6(5): September-October 2016

Available online at ScienceDirect. Procedia Engineering 132 (2015 )

Certified Reference Material - Certificate of Analysis

Transcription:

Identification of the need and uses of a reference standard Stefan Almeling Deputy Head of Laboratory Department, EDQM, Council of Europe

TOPICS General / Definition Role in the monograph How established How presented CRS Database Conclusion

General Chapter of the European Pharmacopoeia 5.12 Pharmaceutical Reference Standards Effective date Jan 1st, 2007 ESTABLISHMENT USE PRESENTATION of pharmaceutical reference standards in general & European Pharmacopoeia reference standards in particular.

Classification of reference standards Type Chemical Reference Substance (CRS) NEW: Herbal Reference Standards (HRS) Biological Reference Preparations Establishment Primary standards (without comparison to an existing standard) Secondary standards (by comparison with a primary standard) Use Qualitative (Identification, system suitability) Quantitative (Assay, external standard)

European Pharmacopoeia Reference Standards A European Pharmacopoeia reference standard is an integral and essential part of the monograph and as such is an official standard that is alone authoritative in case of doubt or dispute. i.e. a «legally binding» standard

European Pharmacopoeia Reference Standards Chemical reference substance (CRS) A chemical compound or mixture of compounds which has been established for use as a standard in an identity test, a purity test and/or an assay as prescribed in a monograph. The standard is valid only for the specific test(s) for which it has been established

Ph. Eur. Reference Standards - 12/2009 CRS for identification 43% CRS for peak ID/SS 10% Assay CRS 14% Herbal CRS 1% Impurity CRS 21% Reference Spectra 8% BRP 3%

CRS FOR IDENTIFICATION A chemical compound which has been established as a standard for qualitative use in an identity test The standard is valid only for the specific test(s) for which it has been established

EXAMPLE: CRS FOR IDENTIFICATION

Impurity CRS / CRS for peak identification & system suitability A chemical compound or mixture of compounds which has been established as a standard for qualitative or quantitative use in a purity test. The standard is valid only for the specific test(s) for which it has been established

CRS used in the test for related substances In general an impurity is to be identified, i.e. located in the chromatogram or electropherogram: - when it has an individual limit and/or - when a correction factor is to be applied

EXAMPLE: Impurity CRS qualitative use - CRS for peak ID & SST / 1

EXAMPLE: Impurity CRS qualitative use CRS for peak ID & SS / 2

EXAMPLE: Impurity CRS qualitative and quantitative use

ASSAY CRS A chemical compound or mixture of compounds which has been established as a standard for quantitative use in an assay. The standard is valid only for the specific test(s) for which it has been established

EXAMPLE: ASSAY CRS Assigned Content (as is): (100 loss on drying) x chromatographic purity (%) / 100 = 99.5% of C 24 H 29 ClN 2 O 5

Establishment of CRS

CRS Establishment Process 1. Need for a new CRS or for a replacement batch 2. Procurement of the proposed candidate 3. Candidate examined by the EDQM Laboratory 4. Filling / Production 5. [ Collaborative study for assay CRS ] 6. Approval by the Group of Experts 7. Adoption by the Ph. Eur. Commission

Step 3: Lab examination of the candidate CRS The extent of analytical testing depends on the intended use of the CRS Identification => confirmation of identity / structure compliance with the monograph Peak ID, system suitability => confirmation of identity & fitness for purpose. External standard => confirmation of the identity / structure & purity Assay: assignment based on interlaboratory study

CRS used in the test for related substances Qualitative use Quantitative use - System suitability - Peak identification - Limit test (e.g. TLC) - Quantitative test (e.g. LC / GC)

Establishment of Impurity CRS : qualitative use Individual impurity : the preferred option. in case of availability problems, the following alternative materials may be employed: Mixtures of impurities Batches containing one or more impurities Spiked samples

Impurity CRS : Quantitative use Individual impurities: value assigned when necessary (purity below 95%) Batch containing the impurity: value assigned in all cases

CRS Establishment Process Need for a new CRS or for a replacement batch Procurement of the proposed candidate Candidate examined by the EDQM Laboratory If required feasibility of production is verified Filling / Production Collaborative study for assay CRS Approved by the Group of Experts Adopted by the Ph. Eur. Commission

Assay CRS Assay methods : LC GC UV spectrophotometry Microbiological assay

Assay CRS Content assignment (method-specific) based on an interlaboratory study involving usually five laboratories i.e. the EDQM Laboratory ; members of the OMCL(*) network and/or Experts of the Ph. Eur.. The manufacturer is normally invited to participate in the study. (*) Official Medicines Control Laboratory

Establishment of assay CRS: internal preliminary work Verification of the structure of the candidate CRS Verification of compliance with the monograph requirements Additional tests, such as residual solvents, DSC purity, non-aqueous titration, content by NMR.

Establishment of assay CRS: interlaboratory study 1. Protocol prepared / tested by the EDQM Laboratory 2. Protocol and samples sent to participants 3. Participants obtain and send results 4. Results evaluated by the EDQM Lab. 5. Report with proposed assigned value 6. Approval from the group of experts 7. Adoption by the Commission

Collaborative study: Example protocol: CRS for LC-assay Determination of water (by KF / coulometry) or Loss on drying Quantitative determination of the impurities by LC Residual solvents by head-space GC

Example: Collaborative trial Benazepril HCl / 1 LC acceptance criteria

Example: Collaborative trial Benazepril HCl / 2

Estimation of the uncertainty of the assigned content Ph. Eur. Commission policy : the uncertainty of the value assigned as a result of an interlaboratory study should be within a predetermined limit which is calculated in relation with the intended use.

Maximum accepted uncertainty % 2.5 2 1.5 1 0.5 0 Dealing with uncertainty 1 2 3 4 5 6 7 8 9 10 11 12 Assay upper limit %

CRS Establishment Process Need for a new CRS or for a replacement batch Procurement of the proposed candidate Candidate examined by the EDQM Laboratory If required feasibility of production is verified Filling / Production / Labelling Collaborative study for assay CRS - report Approved by the Group of Experts Adopted by the Ph. Eur. Commission

Include: Production techniques Powder filling Liquid Filling Freeze drying / evaporation Spray drying

Highly toxic/highly potent substances: glove box under negative pressure for containment and protection of the operators, final external decontamination Hygroscopic substances: controlled humidity Production conditions Substances sensitive to oxidation: under inert gas

CRS Presentation Single use container to minimise the risk of decomposition, contamination, or water uptake Amount per unit Calculated based on amount indicated in the monograph In case of assay CRS produced by powder-filling, the fill weight is twice the amount indicated in the monograph i.e. sufficient for two weighings

LABELLING

CRS for qualitative use

ASSIGNED CONTENT Powder-filled CRS Content (m/m) assigned on an «as is» basis: for example X (%) = [100.0 - (water+solvents)] x %chromatographic purity/100 TO BE WEIGHED - NO NEED TO DRY Freeze-dried CRS The value assigned corresponds to the amount per vial, for example 2.05 mg/vial TO BE RECONSTITUTED, NOT WEIGHED

CRS with assigned content % m/m

CRS with assigned content per vial

PEEL-OFF SECONDARY LABEL Order code Batch number approx. Amount per vial Unique identifier per label Sentences for customs CRS name 2D barcode

Need of a new Ref Std or need of a replacement Procurement of the proposed candidate Candidate examined at the EDQM Lab. Production Inter-laboratory study for assay CRS Approved by the Group of Experts Adopted by the Ph. Eur. Commission Labelling Release Monitoring

Monitoring programme CRS Once established, adopted and released, the CRS undergoes periodic testing in order to ensure its continuous fitness for use. The periodicity of testing depends on the use of the CRS and the stability information available. The extent of testing also depends on the use of the CRS. In general the focus is on the properties that may change during the life cycle of a CRS, i.e.: water content, purity by HPLC, GC or TLC, DSC. No expiry date is given: see batch validity statement

Use of Ph. Eur. CRS/BRP Ph. Eur. CRS/BRP are to be used in conjunction with the corresponding monograph(s). Ph. Eur. CRS/BRP are to be used for the purpose for which they are intended. Any different use is in the responsibility of the user Storage of opened containers is discouraged and is in any case the responsibility of the user

REFERENCE STANDARDS CATALOGUE ON LINE http://www.edqm.eu/medias/fichiers/crs.pdf PDF 3 issues a year

Reference Standards INFORMATION Non-official information intended to facilitate the use of the CRS can be found in the knowledge database and CRS database (website). http://www.edqm.eu -> Databases

Reference standards database Availability Origin Assigned Value Presentation Batch Validity Statement Safety Data Sheets Info on reagents and columns Chromatograms Knowledge database

Ph. Eur. CRS take home messages They are official, legally binding primary standards They constitute an essential part of the monograph They are to be used only for the intended purpose The assay value is assigned as is Their continuous fitness for purpose is assured by a regular monitoring programme User interface / information => website The Ph. Eur. policy on reference standard is reflected in general chapter 5.12

Thank you for your attention.